amifostine anhydrous has been researched along with Acute Myelogenous Leukemia in 15 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Planning therapy for acute myelogenous leukemia (AML) is difficult because of the heterogeneous nature of the disease and varying patient age at presentation." | 2.71 | Cytoprotection in acute myelogenous leukemia (AML) therapy. ( Beardell, F; Brunner, J; Capizzi, R; Cohn, J; Ferbér, A; Filicko, J; Flomenberg, N; Garcia-Manero, G; Grosso, D; Martinez, J; Mookerjee, B; Rose, L; Tice, D; Wagner, JL, 2004) |
| "BFM-83 induction therapy for ANLL (ARA-C + RUB + VP-16) which is applied to children with acute non-lymphoblastic leukemia (ANLL) commonly contributes to severe adverse reactions." | 1.30 | [Cytoprotective effect of amifostine in children during induction therapy according to BFM-83: report on cases]. ( Bodalski, J; Bolanowski, W; Nowak, K; Stolarska, M; Zalewska-Szewczyk, B, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Capelli, D | 2 |
| Saraceni, F | 1 |
| Fiorentini, A | 1 |
| Chiarucci, M | 1 |
| Menotti, D | 1 |
| Poloni, A | 3 |
| Discepoli, G | 2 |
| Leoni, P | 3 |
| Olivieri, A | 3 |
| Yang, B | 1 |
| Wang, HT | 1 |
| Cai, LL | 1 |
| Zhao, Y | 1 |
| Chi, XH | 1 |
| Zhu, HL | 1 |
| Ran, HH | 1 |
| Yang, Y | 1 |
| Yu, RL | 1 |
| Li, SW | 1 |
| Lu, XC | 1 |
| Erikci, AA | 1 |
| Ozturk, A | 2 |
| Karagoz, B | 1 |
| Bilgi, O | 1 |
| Turken, O | 2 |
| Top, C | 1 |
| Kandemir, EG | 1 |
| Pavlova, S | 1 |
| Mayer, J | 1 |
| Koukalova, H | 1 |
| Smardova, J | 1 |
| Grosso, D | 1 |
| Filicko, J | 1 |
| Garcia-Manero, G | 1 |
| Beardell, F | 1 |
| Brunner, J | 1 |
| Cohn, J | 1 |
| Ferbér, A | 1 |
| Martinez, J | 1 |
| Mookerjee, B | 1 |
| Rose, L | 1 |
| Tice, D | 1 |
| Wagner, JL | 1 |
| Capizzi, R | 1 |
| Flomenberg, N | 1 |
| Troiani, E | 1 |
| Montanari, M | 2 |
| Offidani, M | 1 |
| Douay, L | 1 |
| Hu, C | 1 |
| Giarratana, MC | 1 |
| Bouchet, S | 1 |
| Conlon, J | 1 |
| Capizzi, RL | 1 |
| Gorin, NC | 1 |
| Martens, AC | 1 |
| Hagenbeek, A | 1 |
| Curzi, L | 1 |
| Cantori, I | 1 |
| Mancini, S | 1 |
| Masia, MC | 1 |
| Nowak, K | 1 |
| Bolanowski, W | 1 |
| Zalewska-Szewczyk, B | 1 |
| Stolarska, M | 1 |
| Bodalski, J | 1 |
| Preisler, HD | 4 |
| Li, B | 3 |
| Yang, BL | 1 |
| Huang, RW | 1 |
| Devemy, E | 1 |
| Venugopal, P | 4 |
| Tao, M | 3 |
| Chopra, H | 2 |
| Gregory, SA | 2 |
| Adler, S | 2 |
| Sivaraman, S | 2 |
| Toofanfard, P | 1 |
| Jajeh, A | 2 |
| Galvez, A | 2 |
| Robin, E | 1 |
| Hsu, W | 1 |
| Loew, J | 1 |
| Gezer, S | 1 |
| Creech, S | 1 |
| Slivnick, D | 1 |
| Andric, T | 1 |
| Larson, RA | 1 |
| Yang, J | 1 |
| Nayini, J | 2 |
| Horvath, E | 1 |
| Meyer, P | 1 |
| Song, S | 1 |
| Larson, A | 1 |
| Toofanfard, M | 1 |
| Chen, H | 1 |
| Orhan, B | 1 |
| Etiz, D | 1 |
| Yaylaci, M | 1 |
| Uskent, N | 1 |
4 trials available for amifostine anhydrous and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Cytoprotection in acute myelogenous leukemia (AML) therapy.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytoprotection | 2004 |
Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Bone Marrow Cells; Cytokines; Female; fms-Like Tyrosine | 2000 |
Poor prognosis acute myelogenous leukemia: 1 - response to treatment with high dose cytarabine/mitoxantrone/ethyol @ (Amifostine).
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabi | 2000 |
In vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia.
Topics: Amifostine; Cytokines; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin 1 Recep | 2001 |
11 other studies available for amifostine anhydrous and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Feasibility Studies; F | 2020 |
Successful management of acute myeloid leukemia transformed from myelodysplastic syndromes in an elderly patient aged over 80 years old by ultralow dose decitabine combined with amifostine and autologous CIK cells.
Topics: Aged, 80 and over; Amifostine; Azacitidine; Cells, Cultured; Combined Modality Therapy; Cytokine-Ind | 2014 |
Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Dexamethason | 2008 |
High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amifostine; DNA Mutational Analysis; Female; Fungal Prot | 2003 |
A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarub | 2007 |
Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Topics: Amifostine; Antineoplastic Agents; Bone Marrow; Bone Marrow Purging; Bone Marrow Transplantation; Ce | 1995 |
Amifostine (WR2721) for dose escalation in marrow-ablative treatment of leukaemia.
Topics: Amifostine; Animals; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Combined Modali | 1999 |
Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery.
Topics: Amifostine; Animals; Bone Marrow Purging; Cell Survival; Cells, Cultured; Colony-Forming Units Assay | 1999 |
[Cytoprotective effect of amifostine in children during induction therapy according to BFM-83: report on cases].
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Dau | 1998 |
Poor prognosis acute myelogenous leukemia 2--biological and molecular biological characteristics and treatment outcome.
Topics: Amifostine; Base Sequence; DNA Primers; Humans; Leukemia, Myeloid, Acute; Prognosis; Treatment Outco | 2000 |
Acute myeloblastic leukemia achieving complete remission with amifostine alone.
Topics: Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Humans; Leukemia, M | 2002 |